We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+15.02%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.99B
AUM Growth
+$445M
Cap. Flow
-$204M
Cap. Flow %
-5.12%
Top 10 Hldgs %
26.88%
Holding
133
New
39
Increased
28
Reduced
23
Closed
37

Top Sells

Rank Stock Value
1
RRC icon
Range Resources
RRC
+$86.2M
2
CI icon
Cigna
CI
+$69.3M
3
CRM icon
Salesforce
CRM
+$63M
4
ZAYO
Zayo Group Holdings, Inc.
ZAYO
+$61.7M
5
BIIB icon
Biogen
BIIB
+$55.1M

Sector Composition

Rank Sector Weight
1 Healthcare 38.53%
2 Technology 10.63%
3 Communication Services 6.21%
4 Energy 4.56%
5 Consumer Discretionary 4.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PEN icon
51
Penumbra
PEN
$12.6B
$29.7M 0.74%
355,607
+123,715
+53% +$9.36M
PDCO
52
DELISTED
Patterson Companies, Inc.
PDCO
$28.8M 0.72%
635,863
+136,533
+27% +$5.92M
JAZZ icon
53
CALL
Jazz Pharmaceuticals
JAZZ
$16B
$28M 0.7%
+192,900
New +$25.1M
AMT icon
54
American Tower
AMT
$77.7B
$27.5M 0.69%
+226,537
New +$24.9M
HLF icon
55
Herbalife
HLF
$1.26B
$26.3M 0.66%
+906,124
New +$25.2M
V icon
56
Visa
V
$689B
$25.4M 0.64%
+286,015
New +$24.6M
MOH icon
57
Molina Healthcare
MOH
$10.4B
$24.4M 0.61%
534,221
+330,111
+162% +$17.3M
ICLR icon
58
Icon
ICLR
$13B
$23M 0.58%
+288,068
New +$23.6M
MSFT icon
59
Microsoft
MSFT
$2.89T
$21.7M 0.54%
+330,204
New +$21.2M
PYPL icon
60
PayPal
PYPL
$49.5B
$21.7M 0.54%
505,510
-543,620
-52% -$22.7M
ALDR
61
DELISTED
Alder Biopharmaceuticals
ALDR
$21.7M 0.54%
1,045,181
-1,868,770
-64% -$41.4M
ZION icon
62
Zions Bancorporation
ZION
$10B
$21.1M 0.53%
+501,992
New +$21.8M
MYOK
63
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$20.2M 0.51%
1,538,507
+13,922
+0.9% +$178K
VYGR icon
64
Voyager Therapeutics
VYGR
$187M
$19.8M 0.5%
1,495,801
+111,650
+8% +$1.35M
ARAY icon
65
Accuray
ARAY
$26.8M
$19.5M 0.49%
4,101,121
+907,566
+28% +$4.73M
ZAYO
66
DELISTED
Zayo Group Holdings, Inc.
ZAYO
$18.2M 0.46%
554,591
-1,935,960
-78% -$61.7M
KURA icon
67
Kura Oncology
KURA
$901M
$17.9M 0.45%
2,033,229
+54,800
+3% +$402K
RGNX icon
68
Regenxbio
RGNX
$622M
$15.4M 0.39%
798,247
+299,662
+60% +$5.78M
MDCO
69
CALL
DELISTED
Medicines Co
MDCO
$15.4M 0.39%
+315,000
New +$14.4M
ELGX
70
DELISTED
Endologix Inc
ELGX
$14.8M 0.37%
204,379
+94,728
+86% +$6.27M
VMC icon
71
Vulcan Materials
VMC
$36.9B
$14.3M 0.36%
118,745
+23,347
+24% +$2.86M
ARDX icon
72
Ardelyx
ARDX
$1.25B
$14M 0.35%
+1,109,574
New +$14.6M
XYZ
73
Block Inc
XYZ
$48.4B
$13.7M 0.34%
+790,147
New +$12.4M
CSII
74
DELISTED
Cardiovascular Systems, Inc.
CSII
$12.5M 0.31%
441,661
+8,721
+2% +$232K
CRUS icon
75
Cirrus Logic
CRUS
$6.87B
$11.1M 0.28%
183,100
-294,977
-62% -$16.8M

Similar funds

PFM Health Sciences's Q1 2017 Portfolio in Review

As of Q1 2017, PFM Health Sciences held 133 positions worth $3.99B, up 13% from $3.55B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

PFM Health Sciences withdrew a net $204M in Q1 2017, closing 37 positions and reducing 23 holdings. Its most notable exit was Range Resources, an estimated $86.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 41% a quarter earlier, followed by Technology and Communication Services.

Against the trend, PFM Health Sciences opened a new position in Liberty Global Class A worth $111M.

  • PFM Health Sciences's largest Q1 2017 buy was Liberty Global Class A: 3,089,161 shares worth $111M.
  • PFM Health Sciences added most to Marvell Technology in Q1 2017, an estimated $99.1M increase.
  • PFM Health Sciences's biggest Q1 2017 reduction was Cigna, cutting an estimated $69.3M.
  • PFM Health Sciences fully exited Range Resources in Q1 2017, selling an estimated $86.2M.
  • PFM Health Sciences's ten largest holdings make up 27% of its $3.99B portfolio in Q1 2017.
  • PFM Health Sciences opened 39 new positions and closed 37 in Q1 2017.
  • PFM Health Sciences's portfolio value rose 13% quarter-over-quarter to $3.99B.

Based on PFM Health Sciences's 13F filing for Q1 2017, filed 15 May 2017.